UK agency may recommend Sutent for some stromal tumours
This article was originally published in Scrip
The National Institute for health and Clinical Excellence is preparing to recommend Pfizer's Sutent (sunitinib malate) as a treatment option for people with unresectable and/or metastatic malignant gastrointestinal stromal tumours if treatment with imatinib (Novartis's Glivec) has failed because of resistance or intolerance and if they have an Eastern Cooperative Oncology Group performance status of 0 or 1.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.